Mesoblast Ltd - ADR (MESO) Company Profile & Statistics

Mesoblast Ltd - ADR
MESO
(Nasdaq - US)
Closed
11.31
-0.39 (-3.38%)
in:usd•As of: Nov 14, 2024 15:59 UTC -5
After Market:11.1-0.21 (-1.86%)
Open
11.97
High
11.97
Low
11.21

About Mesoblast Ltd - ADR

CEO

Silviu Itescu

Headquarters

level 38, 55 collins street

melbourne, victoria, c3 3000, australia

Auditor

PricewaterhouseCoopers

Employees

Share Holders

N/A

Website

www.mesoblast.com

Industry

biotechnology

Sector

health technology

Company Overview

Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Mesoblast Ltd - ADR Statistics

Valuation Measures

Market Capitalization ²	1.29B
Enterprise Value	1.34B
Enterprise Value/EBITDA (ttm)	-33.08
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	2.37
Price to Sales (ttm)	N/A
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	-199.81%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	-805.32%
Return on Equity (ttm)	N/A
Return on Invested Capital (ttm)	-9.56%
Return on Assets (ttm)	N/A

Income Statement

Revenue (ttm)	5.37M
Revenue Per Share (ttm)	0.05
Gross Profit (ttm)	-14.47M
EBITDA (ttm)³	-40.59M
Net Income Avi to Common (ttm)	-57.40M
Diluted EPS (ttm)	N/A

Share Statistics

Beta (5Y Monthly)	3.47
52-Week Change	363.52%
S&P500 52-Week Change	32.33%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	114.18M
Dividend Yield	0.00%
Float ⁴	92.71M
% Held by Insiders	18.80%
% Held by Institutions	1.43%

Balance Sheet

Total Cash (mrq)	62.96M
Total Cash Per Share (mrq)	0.55
Total Debt (mrq)	114.34M
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	N/A
Quick Ratio (mrq)	1.18%
Book Value Per Share (mrq)	N/A

Cash Flow

Operating Cash Flow Per Share (ytd)	N/A
Free Cash Flow (ytd)	0.00

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Mesoblast Ltd - ADR

Trade With A Regulated Broker